New Cannabis Cultivar 4D2 Secures Patent for Varin and Classical Cannabinoids
The patent disclosure protects a proprietary annual herbaceous cannabis variety, designated ‘4D2’, created through sexual hybridization. The cultivar is chemically distinguished by its simultaneous production of four key cannabinoids: tetrahydrocannabinol (THC), cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV).
Clinical Perspective & Therapeutic Significance
Cultivars that naturally produce propyl-cannabinoids like THCV and CBDV are of high interest for metabolic, neuroinflammatory, and anticonvulsant research. However, because plant patents focus on agricultural genetics rather than refined drug delivery, clinical utility will hinge on whether downstream processors can standardize these ratios into reliable, bioavailable therapeutic products.
Intellectual Property & Market Landscape
Esb LLC is securing intellectual property in the competitive minor-cannabinoid landscape, where THCV and CBDV typically require expensive isolation or synthetic biology techniques due to low natural yields. Establishing a stable plant line that naturally yields both varin and classical cannabinoids allows for more cost-effective botanical extraction for wellness and medical cannabis markets.
Developing plant genetics with elevated minor cannabinoid profiles provides useful raw botanical input, but substantial formulation work and human clinical trials remain necessary to turn raw chemovars into predictable medicines.
Frequently Asked Questions
Why is the co-expression of THCV and CBDV clinically notable?
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
